Merck & Co./$MRK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Merck & Co.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Ticker
$MRK
Sector
Trading on
NYSE
Industry
Pharmaceuticals
Headquarters
Employees
74,000
ISIN
US58933Y1055
Website
Merck & Co. Metrics
BasicAdvanced
$202B
11.68
$6.88
-
$3.16
4.03%
Price and volume
Market cap
$202B
52-week high
$134.63
52-week low
$73.31
Average daily volume
14M
Dividend rate
$3.16
Financial strength
Current ratio
1.41
Quick ratio
0.827
Long term debt to equity
69.182
Total debt to equity
71.992
Dividend payout ratio (TTM)
45.54%
Interest coverage (TTM)
19.06%
Management effectiveness
Return on assets (TTM)
13.81%
Return on equity (TTM)
39.29%
Valuation
Price to earnings (TTM)
11.677
Price to revenue (TTM)
3.177
Price to book
4.18
Price to tangible book (TTM)
18.55
Price to free cash flow (TTM)
11.924
Dividend yield (TTM)
3.93%
Forward dividend yield
4.03%
Growth
Revenue change (TTM)
4.10%
Earnings per share change (TTM)
667.14%
3-year revenue growth (CAGR)
5.80%
3-year earnings per share growth (CAGR)
7.18%
3-year dividend per share growth (CAGR)
5.73%
What the Analysts think about Merck & Co.
Analyst ratings (Buy, Hold, Sell) for Merck & Co. stock.
Merck & Co. Financial Performance
Revenues and expenses
Merck & Co. Earnings Performance
Company profitability
Merck & Co. News
AllArticlesVideos
Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs
Business Wire·9 hours ago
Exclusive: Kennedy's new vaccine adviser was expert witness against Merck vaccine
Reuters·15 hours ago
Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate
Business Wire·19 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Jun16
Merck & Co.
Dividend·Ex-dividend
Jul8
Merck & Co.
Dividend·Payment
$0.81Per share
FAQs
What’s the current market cap for Merck & Co. stock?
Merck & Co. (MRK) has a market cap of $202B as of June 13, 2025.
What is the P/E ratio for Merck & Co. stock?
The price to earnings (P/E) ratio for Merck & Co. (MRK) stock is 11.68 as of June 13, 2025.
Does Merck & Co. stock pay dividends?
Yes, the Merck & Co. (MRK) stock pays dividends to shareholders. As of June 13, 2025, the dividend rate is $3.16 and the yield is 4.03%. Merck & Co. has a payout ratio of 45.54% on a trailing twelve-month basis.
When is the next Merck & Co. dividend payment date?
The next Merck & Co. (MRK) dividend payment is scheduled for July 08, 2025.
What is the beta indicator for Merck & Co.?
Merck & Co. (MRK) does not currently have a Beta indicator.